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Abstract
Background
Sudden unexplained death may be the first manifestation of an unknown inherited cardiac
disease. Current genetic technologies may enable the unraveling of an etiology and the
identification of relatives at risk. The aim of our study was to define the etiology of natural
deaths, younger than 50 years of age, and to investigate whether genetic defects associated
with cardiac diseases could provide a potential etiology for the unexplained cases.
Methods and Findings
Our cohort included a total of 789 consecutive cases (77.19% males) <50 years old (aver-
age 38.6±12.2 years old) who died suddenly from non-violent causes. A comprehensive
autopsy was performed according to current forensic guidelines. During autopsy a cause of
death was identified in most cases (81.1%), mainly due to cardiac alterations (56.87%). In
unexplained cases, genetic analysis of the main genes associated with sudden cardiac
death was performed using Next Generation Sequencing technology. Genetic analysis was
performed in suspected inherited diseases (cardiomyopathy) and in unexplained death, with
identification of potentially pathogenic variants in nearly 50% and 40% of samples,
respectively.
Conclusions
Cardiac disease is the most important cause of sudden death, especially after the age of 40.
Close to 10% of cases may remain unexplained after a complete autopsy investigation.
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Molecular autopsy may provide an explanation for a significant part of these unexplained
cases. Identification of genetic variations enables genetic counseling and undertaking of
preventive measures in relatives at risk.
Introduction
Natural death defines the death primarily attributed to an illness or an internal malfunction of
the body, and not directly influenced by external forces. The forensic pathologists can straight-
forwardly identify the cause of natural death when macroscopic investigations are conclusive
[1]. However, when a macroscopic cause is not evident, the final identification of causality can
become tedious and complicated. Despite comprehensive macroscopic, microscopic as well as
toxicological investigation, around 5%-10% of cases will remain unexplained and will be classi-
fied as sudden unexpected deaths (SUD), often defined in the report as death from a supposed
arrhythmia [2, 3]. In the young population, this percentage may increase up to 30%-50% [4–
6]. Even if the cause of death remains unanswered after a thorough forensic investigation, the
legal work is usually concluded. However, from the medical standpoint, an unidentified etiol-
ogy conveys dangerous clinical implications; these unexplained deaths may be caused by an
inherited cardiac disease, which potentially leaves family members at risk.
In a simplistic classification, deaths caused by cardiac genetic alterations may affect two dif-
ferent disease groups, channelopathies and cardiomyopathies [7]. It is estimated that 10% to
25% of SUD in the adult, and up to one-third in infantile and juvenile SUD, may be explained
by cardiac channelopathies [8–11]. These channelopathies include mainly Long QT syndrome
(LQTS), Short QT syndrome (SQTS), Catecholaminergic Polymorphic Ventricular Tachycar-
dia (CPVT), and Brugada syndrome (BrS) [12]. In addition, pathogenic variations in genes
encoding structural proteins are responsible for cardiomyopathies (Hypertrophic Cardiomy-
opathy (HCM), Dilated Cardiomyopathy (DCM), and Arrhythmogenic Cardiomyopathy
(AC), among others). These cardiomyopathies will usually present anatomo-morphological
changes in the cardiac tissue, which can be diagnosed at autopsy [13], but recent reports have
suggested that in infants they could also be potentially responsible for sudden death in the
structurally normal heart [14, 15].
Because SUD may be the first manifestation of an unknown inherited cardiac disease, the
use of genetic testing, the so-called molecular autopsy, could be determinant in the discovery
of causality, in the identification of genetic carriers in family members, and in the further
adoption of preventive strategies [16, 17]. Despite that current forensic guidelines recommend
molecular autopsy as part of routine protocol in SUD cases, this is seldom performed[18, 19].
This molecular investigation has been mainly limited to research projects, and usually con-
strained to the analysis of the most prevalent genes associated with channelopathies (KCNQ1,
KCNH2, SCN5A and RYR2), leaving several potential candidate genes untested [20, 21]. With
the advent of high-throughput genetic technologies, Next Generation Sequencing (NGS), mas-
sive genetic sequencing has become available [22]. Recent reports have shown that NGS analy-
sis could become an important asset in post-mortem examination [23–27]. To date, only one
comprehensive study has been performed to prove the value of genetic testing in natural death
[28].
In the present work we have addressed this issue by performing a prospective full epidemio-
logical analysis of sudden death in a correlative cohort of SUD victims younger than 50 years
of age, referred for forensic investigation due to out of hospital natural death. The goal was to
define the etiology of natural death in the young, and to investigate whether genetic defects
could contribute to this event. To perform the genetic analysis we have taken advantage of a
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custom-made resequencing panel. By including molecular diagnostic strategies, the ultimate
goal of this work has been to develop a decision algorithm to better refine the forensic investi-
gation, to assess the value of this powerful diagnostic tool in detecting a potential etiology, and
to define which families would benefit from further clinical and genetic investigation.
Methods
Our project was initiated in 2012, in collaboration with Institut de Medicina Legal i Ciències
Forenses de Catalunya (IMLCFC). The IMLCFC oversees and concentrates all SUD cases,
which require forensic investigation. We have focused the project in those cases investigated
by the pathologists in the Catalonia area (population of 7.5 million people).
Forensic analysis
The study was approved by the ethics committee of our Hospital, and follows the Helsinki II
declaration. Our inclusion criteria were victims of sudden death, from natural cause, younger
than 50 years of age. A complete autopsy examination was performed according to current
international regulations [1, 18]. When the macroscopic autopsy was labelled as negative, the
forensic pathologists performed complete histological and toxicological investigation, and col-
lected a blood sample for genetic investigation. We excluded those cases in which the autopsy
was labelled as violent death, including death from drug overdose.
DNA sample
Genomic DNA was extracted with Chemagic MSM I from post-mortem whole blood (Chema-
gic human blood). DNA was checked in order to assure quality (Absorbance 260/280:260/230
should be a minimum 1.8: 2.2 respectively), and was quantified before processing with the
NGS strategy. Spectrophotometric measurements were performed to assess quality ratios of
absorbance; DNA concentration was determined by fluorometry (Qubit, Life Technologies).
DNA integrity was assessed on a 0.8% agarose gel.
NGS sample preparation
The DNA was fragmented (Bioruptor, Diagenode). Library preparation was performed
according to the manufacturer’s instructions (SureSelect XT Custom 0.5–2.9Mb library, Agi-
lent Technologies, Inc). After capture, indexed libraries were sequenced in six-sample pools
per cartridge. Paired-end sequencing process was developed on MiSeq System (Illumina)
using 2x150 bp reads length.
Custom Resequencing panel
Those samples with a good DNA quality were investigated using a custom-made genetic
panel, which included 55 genes associated with SCD (ACTC1, ACTN2, ANK2,CACNA1C,
CACNB2, CASQ2, CAV3, CRYAB, CSRP3, DES, DMD, DSC2,DSG2,DSP, EMD, FBN1, GLA,
GPD1L, HCN4, JPH2, JUP, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, LAMP2, LDB3, LMNA,
MYBPC3,MYH6, MYH7, MYL2, MYL3, MYOZ2, PDLIM3, PKP2, PLN, PRKAG2, RYR2,
SCN4B, SCN5A, SGCA, SGCB, SGCD, TAZ, TCAP, TGFB3,TGFBR2,TNNC1, TNNI3, TNNT2,
TPM1, TTN, and VCL). The panel also included structural proteins, as some recent publica-
tions have suggested that variants in these genes may be associated with SCD, even in the
structurally normal heart [11]. All gene isoforms described in Ensembl 75 (http://www.
ensembl.org/) which have been linked at least with either a RefSeq code (http://www.ncbi.nlm.
nih.gov/refseq/) or CCDS (https://www.ncbi.nlm.nih.gov/CCDS/) were included. Coordinates
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of sequence data were based on UCSC human genome version hg19 (NCBI GRCh37 built).
Biotinylated cRNA probe solution was used as a capture probe (Agilent Technologies). Probes
were designed using eArray (Agilent Technologies) and the design was optimized by Gendiag.
exe S.L. The gene panel final size was 432,512kbp. This custom enrichment gene design is
commercialized by Ferrer inCode as SudD inCode1.
Sanger sequencing
Sanger sequencing was used to confirm non-common (Minor Allele Frequency–MAF- < 1%)
genetic variants detected by NGS, as well as in the genetic analysis of those cases with poor
DNA quality. In this situation, we limited the analysis to the guideline recommended genes
(SCN5A -NM_198056-, KCNQ1 -NM_000218-, KCNH2 -NM_000238-, KCNE1 -NM_000219-
, KCNE2 -NM_172201-, and RyR2 -NM_001035-) [29, 30]. The exons and exon-intron bound-
aries of each gene were amplified (Verities PCR, Applied Biosystems, Austin, TX, USA), the
PCR products were purified (Exosap-IT, Affymetrix, Inc. USB1 Products, Cleveland, OH,
USA) and they were directly sequenced in both directions (Big Dye Terminator v3.1 and
3130XL Genetic Analyzer, both from Applied Biosystems) with posterior SeqScape Software
v2.5 (Life Technologies) analysis, comparing obtained results with the reference sequence
from hg19. The identified variations were compared with DNA sequences from 300 healthy
Spanish individuals (individuals not related to any patient and of the same ethnicity; 600
alleles), as control cases, and contrasted with Human Gene Mutation Database -HGMD-
(http://www.hgmd.cf.ac.uk/ac/index.php), HapMap (http://hapmap.ncbi.nlm.nih.gov/), 1000
genomes project (http://www.1000genomes.org/), Exome Aggregation Consortium–ExAC-
(http://exac.broadinstitute.org/), and Exome Variant Server–EVS–(http://evs.gs.washington.
edu/EVS/). Sequence variants were described following the HGVS rules (http://www.hgvs.org/
), and checked in Mutalyzer (https://mutalyzer.nl/).
Bioinformatics
The secondary bioinformatic analysis of the data obtained included adaptor and low quality
bases trimming on FASTQ files. Trimmed reads were mapped with GEM III. The output were
sorted and uniquely and properly mapped read pairs were selected. Finally, the variant calling
over the cleaned BAM were performed with SAMtools v.1.2 together with an ad hoc developed
script. The final annotation steps provided information included in public databases. Variants
were annotated with dbSNP human build 142 IDs (http://www.ncbi.nlm.nih.gov/SNP/); the
1000 Genomes browser Phase 3 (http://www.1000genomes.org/); the Exome Aggregation
Consortium (ExAC) v.0.3 (http://exac.broadinstitute.org/); NHLBI Exome Sequencing Project
(ESP) ESP6500SI-V2 (http://evs.gs.washington.edu/EVS/); Ensembl information and in-home
database IDs, if available. The Human Gene Mutation Database (HGMD, http://www.hgmd.
cf.ac.uk/ac/index.php) was also consulted to identify previously reported pathogenic muta-
tions. In silico prediction of pathogenicity of novel genetic variations was assessed in CONDEL
software (CONsensus DELeteriousness scores of missense SNVs) (http://bg.upf.edu/condel/),
Mutation Taster (http://www.mutationtaster.org/), and PROVEAN (Protein Variation Effect
Analyzer) (http://provean.jcvi.org/index.php). Alignment of DNA sequences for different spe-
cies was also performed for these novel variations using UniProt database (http://www.
uniprot.org/).
Assessment of pathogenicity
The rare variants (MAF < 1%) were classified according recent ACMG guidelines [31], follow-
ing the criteria:
Genetics of Sudden Unexplained Death
PLOS ONE | DOI:10.1371/journal.pone.0167358 December 8, 2016 4 / 28
Likely/probably benign variants (PBV):
• Variants already described in any of databases, with all in-silico models predicted neutrality.
Variants of uncertain/unknown significance (VUS):
• Novel variants and all in-silico models predicted neutrality or differed between predictions.
• Variants already described in any of databases, and in-silico models differed between
predictions.
Likely/probably pathogenic variants (PPV):
• Likely pathogenic variants reported to be disease-causing but where the author has indicated
that there may be some degree of doubt, or subsequent evidence has come to light in the
literature.
• Radical variants (insertions, deletions or premature stop codons)
• Splice site variants between ± 5 nucleotides, and all in-silico models consulted predicted
pathogenicity.
• Novel variants with all in-silico models predicting pathogenicity.
Disease causing mutations (DM):
• Variants already reported to be disease-causing.
Results
This is a three-year prospective study that was started on February 2012. We have collected a
total of 789 consecutive cases -609 males (77.19%) and 180 females (22.81%)-. The range of age
is from 0 to 50 years of age (average 38.6±12.2 years old). The average age is 39.3±11.2 years in
males and 36.2±14.9 years in females. In order to classify the cases, we have divided the cohort
in groups of 10 years (0–10, 11–20, 21–30, 31–40, 41–50 years old).
Prevalence of natural death according to age
In our cohort, most cases were between 41 and 50 years of age (467 out of 789, 59.19%). A total
of 190 cases (24.08%) were between 31–40 years old and 132 cases (16.73%) were below age 30.
Regarding gender differences, the number of males was higher in all ranges of age, showing
most differences after age 30, with males nearing 80% of cases (Fig 1).
Context in which the natural death took place
Deaths were classified depending whether they took place during stress/exercise, during sleep,
or during routine daily activities. Information about the context of death was provided in 532
cases. The majority of deaths occurred during routine daily activities (376 cases, 70.68%), 98
occurred during sleep (18.42%) and 58 during exercise (10.90%). Deaths during sleep and dur-
ing exercise were more common before the age of 20 (Fig 2).
Etiology of death
Concerning the cause of death, the forensic pathologist directly determined a conclusive cause
of death after macroscopic evaluation (positive macroscopic autopsy) in 506 cases (64.13%),
while a yet inconclusive autopsy (negative macroscopic autopsy) was reported in the
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remaining cases. Most macroscopically positive cases were males (383 cases, 75.69%). Regard-
ing negative autopsy cases, most of these cases were also males (226 cases, 79.86%).
Positive macroscopic autopsy
Out of the 506 cases, the macroscopic investigation defined the following causes of death: car-
diac in 230 cases (45.45%)–mainly coronary artery disease (127 cases)-; vascular (embolism or
hemorrhage) in 137 cases (27.08%); pulmonary/respiratory in 91 cases (17.98%) -infectious
process being responsible for the death in 47 cases, and digestive in 21 cases-; finally, 27 cases
Fig 1. Percentage of natural death according to age and gender. The main percentage of death occurs in last
range of ages. In all ranges of age, males are a high percentage of death. Males are indicated in black color.
Females are indicated in white color.
doi:10.1371/journal.pone.0167358.g001
Fig 2. Context of death. The daily activities had a higher prevalence in cases higher 30 years old. Daily activities
are indicated in black color. Sleep is indicated in white color. Exercise/Stress is indicated in grey color.
doi:10.1371/journal.pone.0167358.g002
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(5.34%), had other less common findings which included 8 non-vascular neurological, 7 carci-
nogenic, 6 endocrinologic, 2 obstetric, 1 infectious and 3 multiorganic failure.
Negative macroscopic autopsy. Microscopic analyses
The macroscopic autopsy was not able to detect the cause of death in 283 cases (35.87%) and
these were labeled as macroscopically negative. To identify a potential cause of death, these
cases were further investigated with histological analysis. This investigation was able to refine
the potential cause of death into the following subgroups: 1) Cardiac, which included coronary
disease in 98 cases (34.63%) (presence of thrombus, of myocardial infarction or of severe coro-
nary stenosis >75%), and 36 (12.72%) potentially cardiac inherited cases, by histological iden-
tification of cardiomyopathy; and, 2) unexplained cases, which included 149 (52.65%) cases
with microscopic findings showing no histological alterations). Among these 149 cases, there
were 23 cases (15.44%) in which death occurred before the first year of age, thus they were
labeled as sudden infant death syndrome (SIDS).
Natural death according to context and final autopsy results
With further inclusion of histological analysis, 364 out of 789 cases (46%) were definitively
labeled as deaths from a cardiac origin. This percentage is underrepresented, as it did not
include the 149 negative cases, some of whom presumably died also from cardiac causes.
Stress/exercise related death was more frequent in cardiac cases (51.72%), while deaths during
daily activity were more prevalent in vascular (20.23%), as well as pulmonary (12.84%) etiolo-
gies (Fig 3).
Natural Death according to age groups
We have divided the results in five groups of age (Fig 4):
Fig 3. Cause of death according to context of death. The distribution showed that cardiac causes were more
prevalent in the context of stress/exercise, while vascular were more prevalent during daily activities. The
unexplained cases had a higher presence in context of sleep and stress/exercise. Daily activities are indicated in
black color. Sleep is indicated in white color. Exercise/Stress is indicated in grey color.
doi:10.1371/journal.pone.0167358.g003
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0–10 years old cohort. This sub-group included a total of 50 cases (6.34%). Of them, 7
cases (14%) died of cardiac causes (2 DCM, 2 myocarditis, 1 LQTS, 2 cardiac cause not speci-
fied), 1 case (2%) of neurological vascular causes, 5 cases (10%) of respiratory affectations (2
infectious, 1 aspiration, 1 asthmatic and 1 obstructive), 3 cases (6%) of cerebral/neurological (2
infectious and 1 malformation), and 1 case (2%) died still birth. Finally, 33 cases (66%) were
left unexplained (23 SIDS and 1 SUDEP) after complete autopsy.
11–20 years old cohort. This sub-group included 20 cases (2.53%). Of them, 4 (20%) died
of cardiac causes (1 HCM, 1 DCM, 1 Congenital and 1 myocarditis), 4 (20%) of vascular causes
(3 pulmonary and 1 digestive injuries), 2 (10%) of respiratory affectations (infectious), 1 (5%)
of cerebral/neurological edema, and 2 (10%) of other causes (1 digestive and 1 endocrinology).
Finally, 7 (35%) cases remained unexplained.
21–30 years old cohort. This sub-group included 62 samples (7.86%). A total of 19
(30.65%) died of cardiac causes (6 coronary, 5 HCM, 1 DCM, 2 AC, 1 myocarditis, 1 congeni-
tal, 1 transplant, 1 valvular and 1 cardiac cause not specified), 9 (14.52%) of vascular injuries (5
pulmonary, 1 aortic, 2 neurological and 1 digestive injuries), 10 (16.13%) of respiratory affecta-
tions (4 infection, 3 edema, 2 aspiration and 1 asthmatic), 1 (1.61%) of cerebral/neurological
pathologies (infection), and 1 (1.61%) of other causes (carcinogenic). Finally, 22 (35.48%)
cases were unexplained.
31–40 years old cohort. This included 190 samples (24.08%). Of them, 82 (43.16%) died
of cardiac causes (49 coronary, 11 cardiac causes not specified, 6 DCM, 8 HCM, 1 AC, 3 myo-
carditis, 2 congenital and 2 fibrosis), 38 (20%) of vascular injuries (15 pulmonary, 9 neurologi-
cal, 8 aortic and 6 digestive), 28 (14.74%) of respiratory affectations (12 infectious, 7 edema, 3
aspiration, 2 asthmatic and 4 obstructive), 3 (1.58%) of cerebral/neurological pathologies (2
infectious and 1 edema), and 8 (4.21%) of other causes (3 digestive, 4 carcinogenic and 1 multi-
organic failure). Finally, 31 (16.32%) cases were unexplained.
41–50 years old cohort. This included 467 samples (59.19%). Of them, 252 (53.96%) died
of cardiac causes (171 coronary, 24 cardiac causes not specified, 18 DCM, 34 HCM, 2 AC, 2
Valvular, 1 pericarditis), 85 (18.20%) of vascular injuries (31 pulmonary, 28 digestive, 19 neu-
rological, and 7 aortic), 46 (9.85%) of respiratory affectations (27 infectious, 10 edema, 6
Fig 4. Cause of death distributed according to age. There is an increase of cardiac causes with age, reaching
54% of cases in the older group of age. However the unexplained cases were common in young below 30 years old,
reaching the 66% of cases in youngest group of age. Cardiac is indicated in black color. Vascular is indicated in
white color. Pulmonary is indicated in grey color. Unexplained is indicated in vertical lines of grey color. Other
causes are indicated in horizontal lines of grey color.
doi:10.1371/journal.pone.0167358.g004
Genetics of Sudden Unexplained Death
PLOS ONE | DOI:10.1371/journal.pone.0167358 December 8, 2016 8 / 28
obstructive, 1 asthmatic, 1 aspiration, and 1 hemorrhagic), and 28 (5.99%) of other causes (17
digestive, 7 carcinogenic, 1 endocrine, 1 multiorganic failure, 1 obstetric and 1 renal infectious
causes). Finally, 56 (11.99%) cases were unexplained.
Molecular autopsy
In addition to defining the etiology of natural death in our cohort, we wanted to assess whether
the use of genetics could improve diagnosis ascertainment, and could better define which, if
any, family members should undergo clinical/genetic evaluation. Thus, we focused our efforts
in those forensic cases with potentially inherited disease or with negative microscopic autopsy:
Potentially inherited subgroup
This study was limited to cases previously considered macroscopically negative by the forensic
pathologist but identified after histological analysis. A total of 32 samples showing histological
alterations associated with cardiomyopathies (10 DCM, 19 HCM, 1 AC, and 2 fibrosis)(Fig 5)
were screened by NGS method. The genetic screening identified a total of 62 rare variants in
25 out of 32 samples (78.13%). Twelve variants (19.35%) were novel. All cases carried at least
one variant in genes codifying for structural proteins. However, 10 cases carried at least one
additional rare variant in genes encoding proteins associated with ion channels or associated
proteins. According to our classification criteria, 2 variants (3.23%) were considered PBV, 39
(62.90%) VUS, 12 (19.35%) PPV, and 9 (14.52%) DM (Table 1).
Unexplained sudden death subgroup
The analysis was performed in 119 samples with negative results after macroscopic and histo-
logical studies.
All samples were analyzed using NGS technology except in 24 samples in which the screen-
ing was limited to Sanger sequencing due to low DNA quality. The Sanger sequencing method
identified at least one rare variant in 6 out of 24 (25%) samples. On the other hand, with the use
of NGS technology we identified 76 out of 95 (80%) samples carrying at least one rare variant.
Concerning NGS samples, 41 of them (43.2%) carried at least one rare variant in genes encoding
proteins associated with ion channels, and 64 (67.3%) carried at least one rare variant in genes
codifying for structural proteins. Overall, we detected 49(41.2%) samples carrying PPV and/or
DM. The genetic screening identified a total of 197 rare variants, 6 detected by Sanger method
and 191 by NGS method. Thirty-six (18.27%) were novel variants. Our criteria classified 16
(8.12%) as PBV, 100 (50.76%) as VUS, 60 (30.46%) as PPV and 21 (10.66%) as DM (Table 2).
Fig 5. Representative microscopic images of samples showing cardiomyopathy. Left. Hypertrophic Cardiomyopathy
(Hematoxylin-Eosin, 20x); Center. Dilated Cardiomyopathy (Hematoxylin-Eosin, 20x); Right. Arrhythmogenic Cardiomyopathy
(Masson’s Trichrome, 10x).
doi:10.1371/journal.pone.0167358.g005
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Concerning ranges of age, the youngest cohort (between 0–10 years of age) included 28
samples (14 males -50%-, and 14 females -50%-). A total of 11 samples were screened by
Sanger method, and 17 by NGS. The genetic screening by both technologies identified a total
of 37 rare variants, 3 detected by Sanger method and 34 by NGS method. Four variants
(10.81%) were novel. We detected 16 samples carrying at least one rare genetic variant
(57.14%). Six samples (21.43%) carried variants in genes associated with ion channels and 12
samples (42.86%) carried variants in genes codifying for structural proteins. We identified 10
(35.71%) samples carrying PPV and/or DM. Finally, pathogenicity criteria classified 6 variants
(16.22%) as PBV, 14 (37.84%) as VUS, 16 (43.24%) as PPV and 1 (2.7%) as DM.
The cohort between 11–21 years of age included 7 samples (5 males -71.43%-, and 2 females
-28.57%-). A total of 2 samples were screened by Sanger method, 5 by NGS. The genetic
screening identified a total of 10 rare variants by NGS method. The Sanger screening did not
identify positive samples carrying rare variants. Of identified variants, 2 (20%) were novel.
NGS method identified 4 samples (80%) carrying at least one rare variant, 3 (42.86%) carried
variants in genes associated with ion channels, and 4 (57.14%) in genes codifying for structural
proteins. Our classification criteria for all samples screened identified 2 (28.57%) samples car-
rying PPV and/or DM. Finally our classification criteria divided the 10 variants in 4 (40%)
VUS, 4 (40%) PPV and 2 (20%) DM.
The cohort between 21–30 years of age included 19 samples (14 males -73.68%-, and 5 females
-26.32%-). All were screened by NGS. The genetic screening identified a total of 42 rare variants.
Of all them, 10 (23.81%) were novel. At least one rare variant was detected in 16 samples
(84.21%), 12 (63.16%) in genes associated with ion channels, and 15 (78.95%) in genes codifying
for structural proteins. Our criteria classified 9 (47.37%) as PPV and/or DM. Finally our classifi-
cation criteria divided the 42 variants in 29 (69.05%) VUS, 10 (23.81%) PPV, and 3 (7.14%) DM.
The cohort between 31–40 years of age included 29 samples (20 males -68.97%-, and 9 females
-31.03%-). A total of 3 samples were screened by Sanger method, 26 by NGS. Sanger screening
identified 2 (66.67%) positive samples for rare variants. The genetic screening by both methods
identified a total of 44 rare variants, 2 (4.5%) detected by Sanger method and 42 (95.5%) by NGS
method. Of all them, 7 (15.91%) were novel. NGS method identified 18 samples (69.23%) carry-
ing at least one rare variant, 6 (33.3%) carried variants in genes associated with ion channels, and
16 (55.2%) in genes codifying for structural proteins. Our classification criteria for all samples
screened identified 13 (44.83%) samples carrying PPV and/or DM. Finally our criteria classified
the 44 variants in 5 (11.36%) PBV, 22 (50%) VUS, 11 (25%) PPV and 6 (13.64%) DM.
The oldest cohort (between 41–50 years old), included 36 samples (28 males -77.78%-, and
8 females -22.22%-). A total of 8 samples were screened by Sanger method, 28 by NGS. The
genetic screening by both methods identified a total of 64 rare variants, 1 (1.6%) detected by
Sanger method and 63 (98.44%) by NGS method. Of all them, 13 (20.31%) were novel. NGS
method identified 24 samples (85.7%) carrying at least one rare variant, 14 (50%) in genes
associated with ion channels, and 20 (71.4%) in genes codifying for structural proteins. Our
criteria classified 14 (38.89%) variants as PPV and/or DM. Finally our criteria classified the 64
variants in 5 (7.81%) PBV, 33 (51.56%) VUS, 17 (26.56%) PPV, and 9 (14.06%) DM.
Discussion
In this prospective cohort we have methodically examined the etiology of natural death by per-
forming a comprehensive investigation that includes a thorough autopsy examination and the
inclusion of an extensive molecular autopsy. We have analyzed a total of 789 SD cases younger
than 50 years of age. By concentrating all our cases in a same institution, a same autopsy proto-
col was followed, according to international forensic recommendations[1, 18].
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Regarding epidemiological data, our data are in concordance with previous studies [32].
Thus we observed similar results in victims’ mean age (39.3 years old), gender (77.19% males),
progressive increase in SD prevalence from age 0 to 50, and predominance of male deaths in
all ranges of age.
The primary cause of SD was cardiac -81.1%-, similar to other cohorts. In 56.87% of cases,
death was labeled from coronary artery disease (CAD), either from evidence of myocardial
infarction or from the identification of severe coronary stenosis, which induced ischemia-
related arrhythmias [28]. This percentage is not much different than the one reported in other
studies, which attributed nearly 40% of deaths to ischemic heart disease[33]. However, in
other reports the percentage of CAD neared 80%. The difference in our percentage is probably
due to the inclusion of population only younger than 50 years of age in our cohort. The per-
centage of CAD-related death increased with age and was highest in population above 40 years
old, as it was expected. In 2015, Vassalini et al reported the presence of ischaemic alterations in
18.5% of a cohort of patients aged less than 40 years, while other studies have underlined
higher incidences of coronary related SCD, with percentages ranging between 48 and 73%
[34–38]. These discrepancies can be explained by the different diagnostic criteria used in sam-
ple selection and age cut-off.
Regarding the situation of death, most CAD-related SD occurred in population older than
40 years of age, and during daily activity or stress/exercise. In the young population, most car-
diomyopathy-related cases died during stress/exercise. These results are in concordance with
other published cohorts and well-known data about exercise being a significant risk factor for
cardiac death.
Macroscopic autopsy was able to define the cause of death in most cases above age 30. How-
ever, in cases below age 30, a negative macroscopic autopsy was the most common scenario.
After adding histological analysis, an additional 17% of cases were labeled as of cardiac origin,
cardiomyopathy or coronary artery disease, increasing the total percentage of cardiac origin to
46%, with CAD totaling 28.5%. In the young population, the main cause of death was from
cardiomyopathies and in younger than 10 years of age, inherited cardiac diseases were the pri-
mary cause, also similar to published reports [39–42]. Nearly 19% of our cases remained as a
negative autopsy, in concordance with a recent publication of Vassalini et al [43]. In other
reports this percentage ranges from 5% to 40%, probably related to the study cohort as well as
autopsy protocols [33, 44].
In 2015, the Swiss Society of Legal Medicine created a multidisciplinary working group,
clinical and molecular geneticists together with cardiologists, in the hope of harmonizing the
approach to the investigation of SCD. The key points of the recommendations were (1.) the
realization of a forensic autopsy procedure for all SCD victims under 40 years of age (molecu-
lar autopsy or post-mortem genetic testing), (2.) the collection and storage of adequate samples
for genetic testing, (3.) communication with the families, and (4.) a multidisciplinary approach
including cardiac genetic counseling[19]. Though, despite these recommendations and the
increasing availability of NGS technology, it is yet seldom performed in most forensic centers
as part of the autopsy. A current matter of argue is who should pay the genetic test. In our
opinion, public health system should assume the cost of these cardiac genetic analysis due to it
is well established that genetic test in cases without conclusive cause of death help to identify
the cause of death in a high number of cases. In addition, these genetic tests also help clinicians
in identification of genetic carriers in family members, doing prevention of SCD in relatives at
risk.
Similarly, according to recent cardiology guidelines[45], the use of molecular autopsy
should be considered in the event of an unexplained sudden cardiac death with a suspicion of
inherited disease. It remains unclear when to suspect an inherited cardiac disease in most
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cases, as death is often the first clinical manifestation in the families. According to these same
guidelines, the identification of a pathogenic variant associated with long QT syndrome or
with CPVT is diagnostic of the disease. Thus, taking these data into account, the use of molec-
ular autopsy appears mandatory in order to attempt to provide a diagnosis, which may benefit
the identification of family members at risk.
For that reason, the aim of our work was to evaluate whether molecular autopsy could
increase the identification of a potential etiology of death. Thus, we performed genetic investi-
gation in all cases classified as microscopic cardiomyopathy as well as in those that remained
unexplained after macro and microscopic autopsy. Thirty-two samples were reclassified as car-
diomyopathies after identification of positive histological alterations. Out of these 32 samples,
19 showed histological changes consistent with a diagnosis of HCM. These results agree with
several studies that report that HCM is the most prevalent cardiomyopathy associated with
SCD. After genetic analysis, 33.9% of cases carried at least one PPV or DM variant, most vari-
ants remaining as VUS.
In addition, we genetically analyzed 119 samples classified as negative autopsy cases.
Genetic analysis identified 41.19% of cases carrying at least one PPV or DM variant, remaining
most variants as VUS. This percentage is in concordance with other genetic studies performed
with NGS panels in autopsy samples [46, 47]. In post-mortem studies in which only a few
genes were analyzed frequencies of detection differ between 11 to 26% [21, 28, 48–51]. Our
percentage is higher due to the largest number of analyzed genes. Of 119 cases classified as
unexplained death, around 40% carry a potentially pathogenic variant. Concretely, in our
cohort, in the population younger than 31 years of age, the percentage of potentially patho-
genic rare variants was 40.4%. Some reports have established that between 10% to 25% of SUD
in the adult, and up to one-third in infantile and juvenile SUD, may be explained by cardiac
channelopathies[8–11]. In most of these studies, the analysis was limited to the main genes
associated with channelopathies. Our higher percentage may be due to a comprehensive
genetic analysis including both genes associated with channelopathies and genes associated
with cardiomyopathies, recently associated with arrhythmic pathologies without any structural
alteration [52, 53]. In concordance with our results, recent studies performed in post-mortem
samples using NGS technology showed percentages of rare variants potentially pathogenic in
30%-40% of samples analyzed [24–26, 54–58].
Out of 119 samples, we identified 21 DM variants in 16 cases (13.44%). Of these, 5 variants
were potentially responsible for LQT, and 2 for BrS. Recent guidelines recommend the use of
post-mortem genetic testing in cases with clinical evidence suggesting a diagnosis of LQTS or
CPVT [29, 45]. Therefore, and according to the guidelines, a diagnosis was reached as a cause
of death. In addition, 51 PPV were identified in 38 cases (31.92%). While their pathogenic role
cannot be fully defined, the potential for an inherited disease makes it essential to further
investigate the family members for segregation. In a recent report, Bagnall et al performed a
NGS analysis in a post-mortem cohort of 490 samples died suddenly between 1–35 years old
[28]. They identify nearly 35% of genetic variants classified as VUS and family segregation clar-
ify the role of nearly 15% of cases concluding that autopsy investigation combined with genetic
testing and family screening is the best way to identify a conclusive cause of death in cases died
suddenly.
Overlapping diseases/genes
In our study we have identified samples classified as cardiomyopathies but carrying rare vari-
ants in genes encoding ion channels and/or associated proteins. Similarly, we have also identi-
fied samples classified as negative autopsy (potential channelopathy) but carrying rare variants
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in genes encoding structural proteins. Several studies have reported the potential pathophysio-
logical mechanisms linking both entities in common genes. Thus, for example, PKP2 (encoding
plakophilin-2), is the main gene associated with AC and has been reported playing a pathogenic
role in BrS [52, 53] despite additional studies in large cohorts should be performed to clarify
this point [59]. In addition, alterations in SCN5A (encoding the sodium channel), the main
gene associated with BrS, have been reported in 1–2% cases of DCM [60], and even AC [61]. In
concordance with similar results from recent studies [62], this could suggest that a malignant
arrhythmia could appear in early stage before a structural alteration is developed. However, fur-
ther studies in larger cohorts should be performed to prove or refute this hypothesis.
Compound/Multigenic variants
In almost 50% of samples, more than one rare genetic variant was identified, even in the same
gene in some cases. Most of these rare genetic variants are at present of unknown significance.
However, whether they have a role in the final risk of sudden cardiac death is unknown. Their
potential effect as genetic modifiers (either detrimental or protective) of the phenotype is well
accepted, but larger and more comprehensive studies will be needed to obtain conclusive data.
Limitations
The first and main limitation already mentioned above is the lack of family members in order
to perform a clinical-genetic segregation. The family segregation is crucial to clarify the role of
identified genetic variants in each case/family. In addition, functional studies could help eluci-
date the pathogenic role of the variants in arrhythmogenesis but in vitro evidence of channel
dysfunction associated with specific variants may not necessarily directly translate into a clini-
cal phenotype in the complex biological environment of the human cardiovascular system.
Finally, cases without any identified genetic variation could carry a defect in other genes not
included in our NGS custom-panel.
Conclusions
In a prospective cohort of 789 cases of natural death, younger than 50 years of age, we show
that cardiac alterations are the most common cause of death, concretely coronary artery
Fig 6. Proposal of flow chart as forensic protocol guide for Sudden Death cases. In cases less than 30 years old
with a negative macroscopic autopsy or cases suspected of cardiomyopathy should be studied by genetics. Older
cases must wait for histological analyses before be studied by genetics.
doi:10.1371/journal.pone.0167358.g006
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disease. While forensic investigation can determine the cause of death in most cases, nearly
19% of cases remain unanswered after a thorough autopsy investigation. The use of NGS
genetic analysis has been advocated as an important complement to the investigation of death,
and the incorporation of molecular autopsy in current guidelines attest to its value, according
to the experts. The molecular autopsy may help identify the cause of death in a large percent-
age of cases remaining as negative after autopsy. In our cases without conclusive cause of
death, we identified nearly 35% of PPV and nearly 15% of DM variants therefore reaching a
conclusive diagnosis according to the guidelines. In our study we show that genetic analysis
should be performed when there is a suspicion for an inherited cardiac disease after macro-
scopic or histological analysis, and when all tests have excluded a cause of death. Of notice, in
SUD victims older than 30, it is important to exclude coronary disease by histology before pro-
ceeding with molecular autopsy, as this is the most common cause of death in that population.
Our data show that before age 30, despite histological analysis should be performed in order to
identify any microscopic alteration, the genetic analysis should be undertaken right away
because the percentage of microscopic cardiac alterations is very low. In addition, even when
histology identifies any microscopic cardiac alteration, the genetic results are a helpful comple-
ment of alterations identified in order to conclude cause of death. Consequently, we have pro-
posed a simple forensic recommendation about molecular autopsy in Sudden Death cases (Fig
6). The evaluation of relatives should include an appropriate genetic counseling and will allow
the implementation of preventive measures to the relatives at risk to prevent new cases of
SCD.
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